tbuckley/cabot-search huggingface dataset:
Deadly Adolescent Intimate Partner Violence and the Need for Youth-Specific Strategies for Effective Intervention
Authors: Caroline J. Kistin, Emily F. Rothman, Megan H. Bair-Merritt
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia
Authors: Anjali S. Advani, Brenda Cooper, Valeria Visconte, Paul Elson, Ricky Chan, Jennifer Carew, Wei Wei, Sudipto Mukherjee, Aaron Gerds, Hetty Carraway, Aziz Nazha, Betty Hamilton, Ronald Sobecks, Paolo Caimi, Benjamin Tomlinson, Ehsan Malek, Jane Little, Alexander Miron, John Pink, Jaroslaw Maciejewski, Allison Unger, Matt Kalaycio, Marcos de Lima, Mikkael A. Sekeres
Journal: Clinical Cancer Research (2019)

Abstract Purpose: The prognosis of patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) remains poor, and novel therapies are needed. The proteasome pathway represents a potential therapeutic target. A phase I trial of the second-generation proteasome inhibitor ixazomib in combination with MEC (mitoxantrone, etoposide, and cytarabine) was conducted in patients with R/R AML. Patients and Methods: Dose escalation of ixazomib was performed using a standard 3 × 3 design. Gene-expression profiling was performed on pretreatment and posttreatment bone marrow or blood samples. Results: The maximum tolerated dose of ixazomib in combination with MEC was 1.0 mg. The dose limiting toxicity was thrombocytopenia. Despite a poor risk population, the response rate [complete remission (CR)/CR with incomplete count recovery (CRi)] was encouraging at 53%. Gene-expression analysis identified two genes, IFI30 (γ-interferon inducible lysosomal thiol reductase) and RORα (retinoic orphan receptor A), which were significantly differentially expressed between responding and resistant patients and could classify CR. Conclusions: These results are encouraging, but a randomized trial is needed to address whether the addition of ixazomib to MEC improves outcome. Gene-expression profiling also helped us identify predictors of response and potentially novel therapeutic targets.
World Health Organization Treatment Recommendations for Nonsevere Fast-Breathing Pneumonia Need to Be Updated
Authors: Maeve M. Woeltje, Jason G. Newland, Indi Trehan
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Pattern of first-site failure and salvage treatment in patients with inoperable stage III non-small cell lung cancer after chemoradiotherapy
Authors: C. Eze, J. Taugner, L. Käsmann, O. Roengvoraphoj, N.-S. Schmidt-Hegemann, M. Dantes, C. Belka, F. Manapov
Journal: Annals of Oncology (2019)

Background: The standard of care treatment for inoperable stage III NSCLC is concurrent chemoradiotherapy (CRT) followed by consolidation with durvalumab. Loco-regional and distant recurrences remain common. Herein, we examine pattern of first-site failure and salvage treatment. Methods: We analysed the medical charts of 99 patients treated with CRT. Scans from date of first-site failure were fused with the delivered treatment plans. Recurrences were identified as in-field recurrence (IFR), out-of-field recurrence (OFR) [outside 50Gy isodose line] and distant metastases (DM). Using the Kaplan-Meier method with log-rank test for univariate analysis, the effect of salvage surgery (S), radiotherapy (sRT), chemotherapy (sCT) and immunotherapy (sIO) on overall survival (OS) was evaluated. Results: With a median follow-up of 17.2 months, the mOS for all patients was 20.8 months. 26 patients (26%) with IFR had a mOS of 19.3 months. In patients who survived at least 12 months from initial diagnosis (74%), IFR was a significant negative prognosticator (mOS 19.3 vs 40.0 months; p < 0.001). 25 (25%) patients developed OFR with no significant impact on survival (27.1 vs 20.8 months, p = 0.313). 3 (12%) patients with OFR underwent salvage surgery (p = 0.057) and were still alive at the time of this analysis. 5 (20%) patients underwent sRT with a mOS of 71.2 vs 19.1 months (p = 0.014). 13 (52%) patients with OFR received sCT; mOS 26.4 vs 32.7 mo. (p = 0.644;) and 4(16%) pts received sIO (mOS: 64.6 vs 26.4 months; p = 0.222). Distant and brain relapse were detected in 42 (42%) and 16 (16%) patients; mOS 19.1 vs. 22.9 months (p = 0.819) and 19.1 vs 20.8 mo. (p = 0.635), respectively. 15 (94%) patients with brain relapse received cranial radiotherapy: 7 (47%) whole brain irradiation and 8 (53%) stereotactic radiosurgery (mOS 15.3 vs. 37.8 mo.; p = 0.064). Conclusions: IFR was a significant negative predictor of OS in patients, who survived >1 year after initial diagnosis. Patients with OFR benefit most from salvage operation and/or radiotherapy. Furthermore, we observed survival benefit in patients who received SRS vs. WBRT for brain relapse. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
FRI-474-AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma
Authors: Massimo Iavarone, Enrico Galmozzi, Annalisa De Silvestri, Andrea Casadei Gardini, Fabio Piscaglia, Giorgia Marisi, Floriana Facchetti, Luca Faloppi, Luca Ielasi, Francesca Benevento, Mario Scartozzi, Stefano Cascinu, Angelo Sangiovanni, Carmine Tinelli, Pietro Lampertico
Journal: Journal of Hepatology (2019)
TCTAP C-001 Ostial LM PCI Followed by LM-bifurcation Mini-crush Technique in a ESRF Patient with ACS
Authors: Chu Zhen Quek, Benjamin Leo Cheang Leng, Hou Tee Lu, Jiyen Kam, Kai Ping Ang, Chuey Yan Lee
Journal: Journal of the American College of Cardiology (2019)
THU-262-A modified Glasgow alcoholic hepatitis score incorporating the neutrophil-to-lymphocyte ratio is superior to other baseline scores of prognosis in alcoholic hepatitis
Authors: Ewan Forrest, Natasha Storey, Rohit Sinha, Stephen Atkinson, Nikhil Vergis, Michael Allison, Paul Richardson, Steven Masson, Mark Thursz, Peter Hayes
Journal: Journal of Hepatology (2019)
Record-Breaking Performance in a 70-Year-Old Marathoner
Authors: Austin T Robinson, Joseph C Watso, Matthew C Babcock, Michael J Joyner, William B Farquhar
Journal: New England Journal of Medicine (2019)

Oxygen Intake in 70-Year-Old Marathoner This letter presents data suggesting that a master athlete’s ability to maintain a remarkably high percentage of maximum oxygen uptake played a role in enabl...
PS-006-MBOAT7 downregulation induces hepatic lipid accumulation
Authors: Marica Meroni, Paola Dongiovanni, Miriam Longo, Guido Alessandro Baselli, Fabrizia Carli, Raffaela Rametta, serena pelusi, Sara Badiali, Marco Maggioni, Anna Ludovica Fracanzani, Stefano Romeo, Amalia Gastaldelli, Stefano Gatti, Luca Valenti
Journal: Journal of Hepatology (2019)
Regulation of gene expression by miR-144/451 during mouse erythropoiesis
Authors: Peng Xu, Lance E. Palmer, Christophe Lechauve, Guowei Zhao, Yu Yao, Jing Luan, Anastasios Vourekas, Haiyan Tan, Junmin Peng, John D. Schuetz, Zissimos Mourelatos, Gang Wu, Mitchell J. Weiss, Vikram R. Paralkar
Journal: Blood (2019)
A Human Organotypic Microfluidic Tumor Model Permits Investigation of the Interplay between Patient-Derived Fibroblasts and Breast Cancer Cells
Authors: Danh D. Truong, Alexander Kratz, Jin G. Park, Eric S. Barrientos, Harpinder Saini, Toan Nguyen, Barbara Pockaj, Ghassan Mouneimne, Joshua LaBaer, Mehdi Nikkhah
Journal: Cancer Research (2019)

Tumor-stroma interactions significantly influence cancer cell metastasis and disease progression. These interactions are partly comprised of the cross-talk between tumor and stromal fibroblasts, but the key molecular mechanisms within the cross-talk that govern cancer invasion are still unclear. Here, we adapted our previously developed microfluidic device as a 3D in vitro organotypic model to mechanistically study tumor-stroma interactions by mimicking the spatial organization of the tumor microenvironment on a chip. We cocultured breast cancer and patient-derived fibroblast cells in 3D tumor and stroma regions, respectively, and combined functional assessments, including cancer cell migration, with transcriptome profiling to unveil the molecular influence of tumor-stroma cross-talk on invasion. This led to the observation that cancer-associated fibroblasts (CAF) enhanced invasion in 3D by inducing expression of a novel gene of interest, glycoprotein nonmetastatic B (GPNMB), in breast cancer cells, resulting in increased migration speed. Importantly, knockdown of GPNMB blunted the influence of CAF on enhanced cancer invasion. Overall, these results demonstrate the ability of our model to recapitulate patient-specific tumor microenvironments to investigate the cellular and molecular consequences of tumor-stroma interactions. SIGNIFICANCE: An organotypic model of tumor-stroma interactions on a microfluidic chip reveals that CAFs promote invasion by enhancing expression of GPNMB in breast cancer cells.
PS-193-Phase 2 open-label study with a placebo-controlled drug withdrawal period of the apical sodium-dependent bile acid transporter inhibitor maralixibat in children with Alagille Syndrome: 48-week interim efficacy analysis
Authors: Emmanuel Gonzales, Ekkehard Sturm, Michael Stormon, Etienne Sokal, Winita Hardikar, Florence Lacaille, Dorota Gliwicz, Loreto Hierro, Thomas Jaecklin, Joan Gu, Nirav K. Desai, Alejandro Dorenbaum, Ciara Kennedy, Alastair Baker, Emmanuel Jacquemin
Journal: Journal of Hepatology (2019)
SAT-055-Dobutamine counteracts the decrease in cardiac output after terlipressin in patients with cirrhosis and impaired kidney function but does not improve GFR: A randomised exploratory trial
Authors: Mads Israelsen, Emilie Dahl, Bjørn Madsen, Signe Wiese, Flemming Bendtsen, Søren Møller, Annette Dam Fialla, Prof. Boye L. Jensen, Aleksander Krag
Journal: Journal of Hepatology (2019)
THU-230-HBV and HDV confection trends in HIV+ patients in Vienna
Authors: Caroline Schmidbauer, David Chromy, David Bauer, Victor Schmidbauer, Mattias Mandorfer, Armin Rieger, Florian Mayer, Heidemarie Holzmann, Michael Trauner, Michael Gschwantler, Thomas Reiberger
Journal: Journal of Hepatology (2019)
PS-058-The socio-economic burden of NASH in Europe and the United States: The gain study
Authors: leonardo Ruiz, Rosa Willock, Thomas Russell, George Morgan, Jamie O’hara, Quentin Anstee, Ingo Van Thiel, Alan Finnegan, Judy Rhys, Vanessa Hebditch, Mzwandile Mabhala, PD Dr. Schattenberg Jörn, Manuel Romero-Gómez, Elisabetta Bugianesi, Vlad Ratziu, Tatjana Reic, Gregory Guzauskas, Bengt Jönsson, Anthony Hatswell
Journal: Journal of Hepatology (2019)
PS-087-Fecal microbiota capsules are safe and effective in patients with recurrent hepatic encephalopathy: A randomized, blinded, placebo-controlled trial
Authors: Jasmohan S Bajaj, Nita Salzman, Chathur Acharya, Richard Sterling, Andrew Fagan, Melanie White, Edith Gavis, Majdi Osman, Michael Hayward, Mary Holtz, Scott Matherly, Richard Todd Stravitz, Mohammad Siddiqui, Michael Fuchs, Binu John, Masoumeh Sikaroodi, Patrick Gillevet
Journal: Journal of Hepatology (2019)
Metformin in 2019
Authors: James Flory, Kasia Lipska
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RnBeads 2.0: comprehensive analysis of DNA methylation data
Authors: Fabian Müller, Michael Scherer, Yassen Assenov, Pavlo Lutsik, Jörn Walter, Thomas Lengauer, Christoph Bock
Journal: Genome biology (2019)

DNA methylation is a widely investigated epigenetic mark with important roles in development and disease. High-throughput assays enable genome-scale DNA methylation analysis in large numbers of samples. Here, we describe a new version of our RnBeads software - an R/Bioconductor package that implements start-to-finish analysis workflows for Infinium microarrays and various types of bisulfite sequencing. RnBeads 2.0 ( https://rnbeads.org/ ) provides additional data types and analysis methods, new functionality for interpreting DNA methylation differences, improved usability with a novel graphical user interface, and better use of computational resources. We demonstrate RnBeads 2.0 in four re-runnable use cases focusing on cell differentiation and cancer.
Abrupt Onset of Dysphagia, Arthritis, Joint Contractures, and Sheets of Monomorphous Waxy Papules
Authors: Traci Pawlitschek, Tamar Hajar, Nicole Fett
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Guideline: Starting dual antiplatelet therapy ≤ 24 h after high-risk TIA or minor ischemic stroke is recommended
Authors: Ken Uchino
Journal: Annals of Internal Medicine (2019)

Source Citation Prasad K, Siemieniuk R, Hao Q, et al. Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. BMJ. 2018;363:k5130. 30563885
FRI-457-Comparative long-term outcomes of laparoscopic liver resection and radio frequency ablation for hepatocellular carcinoma: Location of tumor matters
Authors: Jai Young Cho, Ho-Seong Han, Sook-Hyang Jeong, Jin-Wook Kim, Eun Sun Jang, YoungRok Choi, Boram Lee
Journal: Journal of Hepatology (2019)
Abstract 16342: Feasibility and Safety of Intra-operative Mapping for Diagnosis of the Substrate of Atrial Fibrillation
Authors: Lisette van der Does, Ameetha Yaksh, Charles Kik, Paul Knops, Frans Oei, Pieter van de Woestijne, Eva Lanters, Christophe Teuwen, Ad Bogers, Maurits Allessie, Natasja de Groot
Journal: Circulation (2015)

Introduction: Multi-site, high-resolution mapping can be used to identify either the trigger or substrate perpetuating atrial fibrillation (AF). The goal of this study was to assess the feasibility and safety of a new high-resolution epicardial mapping approach. Hypothesis: Epicardial atrial mapping of the entire atria can be safely performed as a routine procedure during cardiac surgery. Methods: Epicardial mapping of the entire right atrium, left atrium and Bachmann’s Bundle was performed in 291 patients (218 male, age:66±11yrs) undergoing elective surgery during sinus rhythm (SR) and (induced) AF using high-resolution mapping arrays with inter-electrode distances of 1-2mm. Electrophysiological parameters were quantified and designated to anatomical quadrants of 1cm2. Results: AF was non-inducible in 36 patients. Hemodynamic parameters (mean arterial pressure, right atrial pressure, BIS score, ST-T segment alterations) before and during SR mapping were comparable (P&lt;0.22). During AF, only mean arterial pressure (71±11 versus 67±10mmHg (P&lt;0.004)) and right atrial pressure (10±4 versus 11±4mmHg (P&lt;0.0001)) decreased. Total mapping time during SR or AF was respectively 3±1min. and 4±2min. Beat-to-beat variation of SR cycle length and peak-to-peak amplitude of unipolar potentials were respectively 0.04±14.42ms and -0.01±0.53mV, reflecting stability of the mapping array. Complications were not observed. Conclusions: Our novel intra-operative epicardial atrial mapping approach can be safely applied during both SR and AF. This mapping approach is the first technique allowing quantification of the arrhythmogenic substrate in the individual patient thereby taking the first step towards personalizing treatment of AF.
Correction: Gene Regulatory Network Analysis Identifies Sex-Linked Differences in Colon Cancer Drug Metabolism
Authors: Camila M. Lopes-Ramos, Marieke L. Kuijjer, Shuji Ogino, Charles S. Fuchs, Dawn L. DeMeo, Kimberly Glass, John Quackenbush
Journal: Cancer Research (2019)

In the original version of this article (1), in the Disclosure of Potential Conflicts of Interest section, Dr. Charles S. Fuchs did not report consulting work with the biotechnology and pharmaceutical industry focused on cancer drug development. With respect to an analysis of molecular features that drive sex differences in colorectal cancer development, Dr. Fuchs did not consider that his consulting work in drug development represented a potential conflict of interest or a relevant financial activity to the submitted work. But in the interest of full transparency, Dr. Fuchs has requested that his disclosures be added to the publication. This section has been updated in the latest online HTML and PDF versions of the article.
THU-403-The consensus hepatitis C cascade of care: Methodology and initial findings from three countries
Authors: Kelly Safreed-Harmon, Sarah Blach, Soo Aleman, Knut Boe Kielland, Signe Bollerup, Graham Cooke, Olav Dalgard, John Dillon, Gregory Dore, Ann-Sofi Du Berg, Jason Grebely, Havard Midgard, kholoud porter, Homie Razavi, Mark Tyndall, Nina Weis, Jeffrey Lazarus
Journal: Journal of Hepatology (2019)
Phthalate Exposure and Breast Cancer Incidence: A Danish Nationwide Cohort Study
Authors: Thomas P. Ahern, Anne Broe, Timothy L. Lash, Deirdre P. Cronin-Fenton, Sinna Pilgaard Ulrichsen, Peer M. Christiansen, Bernard F. Cole, Rulla M. Tamimi, Henrik Toft Sørensen, Per Damkier
Journal: Journal of Clinical Oncology (2019)

PURPOSE Phthalate exposure is ubiquitous and especially high among users of drug products formulated with phthalates. Some phthalates mimic estradiol and may promote breast cancer. Existing epidemiologic studies on this topic are small, mostly not prospective, and have given inconsistent results. We estimated associations between longitudinal phthalate exposures and breast cancer risk in a Danish nationwide cohort, using redeemed prescriptions for phthalate-containing drug products to measure exposure. METHODS We ascertained the phthalate content of drugs marketed in Denmark using an internal Danish Medicines Agency ingredient database. We enrolled a Danish nationwide cohort of 1.12 million women at risk for a first cancer diagnosis on January 1, 2005. By combining drug ingredient data with the Danish National Prescription registry, we characterized annual, cumulative phthalate exposure through redeemed prescriptions. We then fit multivariable Cox regression models to estimate associations between phthalate exposures and incident invasive breast carcinoma according to tumor estrogen receptor status. RESULTS Over 9.99 million woman-years of follow-up, most phthalate exposures were not associated with breast cancer incidence. High-level dibutyl phthalate exposure (≥ 10,000 cumulative mg) was associated with an approximately two-fold increase in the rate of estrogen receptor–positive breast cancer (hazard ratio, 1.9; 95% CI, 1.1 to 3.5), consistent with in vitro evidence for an estrogenic effect of this compound. Lower levels of dibutyl phthalate exposure were not associated with breast cancer incidence. CONCLUSION Our results suggest that women should avoid high-level exposure to dibutyl phthalate, such as through long-term treatment with pharmaceuticals formulated with dibutyl phthalate.
2019 AATS/ACC/ASE/SCAI/STS Expert Consensus Systems of Care Document: A Proposal to Optimize Care for Patients With Valvular Heart Disease
Authors: Rick A. Nishimura, Patrick T. O’Gara, Joseph E. Bavaria, Ralph G. Brindis, John D. Carroll, Clifford J. Kavinsky, Brian R. Lindman, Jane A. Linderbaum, Stephen H. Little, Michael J. Mack, Laura Mauri, William R. Miranda, David M. Shahian, Thoralf M. Sundt
Journal: Journal of the American College of Cardiology (2019)